Given the widespread clinical application and proven effectiveness of GLP-1 RAs, GLP/GIP RA for managing T2DM and obesity, clinicians should remain aware of potential gastrointestinal side effects. This evidence concerns the gene GCG and obesity due to melanocortin 4 receptor deficiency.